Atossa Genetics (ATOS) Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Inves – Benzinga

Posted: September 8, 2022 at 2:37 am

SEATTLE, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. ATOS, a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious disease with a current focus on breast cancer and COVID-19, announced today that Kyle Guse, General Counsel & Chief Financial Officer will attend the 24th Annual H.C. Wainwright Global Investment Conference being held on September 12 14, 2022 at the Lotte New York Palace.

Mr. Guse will be available for one-on-one meetings. To request a meeting and to register for the conference, click below:

Annual Global Investor Conference

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19.

For more information, please visitwww.atossatherapeutics.com

Contact:

Atossa Therapeutics, Inc.Kyle Guse, General Counsel and Chief Financial Officerkyle.guse@atossainc.com

See the original post here:
Atossa Genetics (ATOS) Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Inves - Benzinga

Related Post